PAR 7.02% 26.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-191

  1. 4,244 Posts.
    lightbulb Created with Sketch. 6726
    There is nothing in this world that is completely flawless, even Diamonds arent completely flawless for example.
    You have to do a cost benefit analysis with everything. Even if it is true and it does affect 7 out of x number if patients, in my view the advantages far outweigh the disadvantages.Why hasn’t this shown up before?Elmiron has been used for how many years?

    I agree with Equitable, maybe there will be future reports of some of the disadvantages, I have previously reported on some very tiny negatives but they haven’t as yet swayed me, I have presented many positives and you know my stance, I’m trying not to be a one eye pirate/investor and take in all views both positive and negative but the best answers will not come from me, they will come from the patients and finally the pain relief and ability to have increased joint function.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
26.5¢
Change
-0.020(7.02%)
Mkt cap ! $92.69M
Open High Low Value Volume
29.0¢ 29.0¢ 26.0¢ $229.3K 833.1K

Buyers (Bids)

No. Vol. Price($)
9 89111 26.0¢
 

Sellers (Offers)

Price($) Vol. No.
27.0¢ 25136 1
View Market Depth
Last trade - 16.10pm 25/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.